Substituted aurone derivatives
A method for treating a microbial infection is disclosed. The method includes administering to a patient a pharmaceutical composition containing a compound of formula (IA) where each R is independently H, OH, Br, Cl, I, amino, thiol, nitro, C1-4 alkoxy, C1-4 alkenyloxy, C2-6 alkoxyalkyleneoxy, C1-4...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | ALEXANDRA SANTANA-SORENSON JACK B JIANG WAI-LAM ALEX CHU THOMAS B. JENSEN JAMES B. MCALPINE CATHERINE NOBLE SUNIL RATNAYAKE BIRGITTE SOKILDE ANGELA M. STAFFORD FLEMMING R. JENSEN |
description | A method for treating a microbial infection is disclosed. The method includes administering to a patient a pharmaceutical composition containing a compound of formula (IA) where each R is independently H, OH, Br, Cl, I, amino, thiol, nitro, C1-4 alkoxy, C1-4 alkenyloxy, C2-6 alkoxyalkyleneoxy, C1-4 alkylthio, C3-18 alkyl, or C3-18 alkenyl; or two adjacent R's, taken together, are a C2-18 bivalent moiety containing at least one oxygen atom, substituted or disubstituted with A or B or both, A being H, OH, Br, Cl, I, amino, or thiol, and B being H, C1-10 alkyl, C2-18 alkenyl, or C6-18 aryl; provided at least two Rs are not H; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with two substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with three substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a prenyl substituent and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be H or OH; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a substituent containing three rings and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; X is C4-10 alkyl, C4-20 alkenyl, or a C4-20 single, C6-20 bridged, or C6-20 fused ring moiety containing cycloalkyl, cycloalkenyl, aryl, heterocycle, or heteroaryl, where X is substituted with H, OH, Cl, Br, I, amino, cyano, nitro, alkyl, alkoxy, alkenyl, or alkenyloxy; provided that if X is a heteroaryl or heterocyclic moiety where two Rs are each OH and meta to each other, then the remaining R is H and ortho to each of the two hydroxyls, and Y and Z are each O, and a ring atom of X is linked directly to the sp carbon atom adjacent to X, then substituted with H, OH, Cl, Br, I, amino, cyano, alkyl, alkoxy, alkenyl, or alkenyloxy; and each of Y and Z is independently selected from O, S, and NH; or a pharmaceutically acceptable salt or ester thereof. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU751213BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU751213BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU751213BB23</originalsourceid><addsrcrecordid>eNrjZJALLk0qLsksKS1JTVFILC3Kz0tVSEktyixLLMksSy3mYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxjqHmpoZGhsZOTkbGRCgBAPG_JM0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Substituted aurone derivatives</title><source>esp@cenet</source><creator>ALEXANDRA SANTANA-SORENSON ; JACK B JIANG ; WAI-LAM ALEX CHU ; THOMAS B. JENSEN ; JAMES B. MCALPINE ; CATHERINE NOBLE ; SUNIL RATNAYAKE ; BIRGITTE SOKILDE ; ANGELA M. STAFFORD ; FLEMMING R. JENSEN</creator><creatorcontrib>ALEXANDRA SANTANA-SORENSON ; JACK B JIANG ; WAI-LAM ALEX CHU ; THOMAS B. JENSEN ; JAMES B. MCALPINE ; CATHERINE NOBLE ; SUNIL RATNAYAKE ; BIRGITTE SOKILDE ; ANGELA M. STAFFORD ; FLEMMING R. JENSEN</creatorcontrib><description>A method for treating a microbial infection is disclosed. The method includes administering to a patient a pharmaceutical composition containing a compound of formula (IA) where each R is independently H, OH, Br, Cl, I, amino, thiol, nitro, C1-4 alkoxy, C1-4 alkenyloxy, C2-6 alkoxyalkyleneoxy, C1-4 alkylthio, C3-18 alkyl, or C3-18 alkenyl; or two adjacent R's, taken together, are a C2-18 bivalent moiety containing at least one oxygen atom, substituted or disubstituted with A or B or both, A being H, OH, Br, Cl, I, amino, or thiol, and B being H, C1-10 alkyl, C2-18 alkenyl, or C6-18 aryl; provided at least two Rs are not H; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with two substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with three substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a prenyl substituent and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be H or OH; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a substituent containing three rings and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; X is C4-10 alkyl, C4-20 alkenyl, or a C4-20 single, C6-20 bridged, or C6-20 fused ring moiety containing cycloalkyl, cycloalkenyl, aryl, heterocycle, or heteroaryl, where X is substituted with H, OH, Cl, Br, I, amino, cyano, nitro, alkyl, alkoxy, alkenyl, or alkenyloxy; provided that if X is a heteroaryl or heterocyclic moiety where two Rs are each OH and meta to each other, then the remaining R is H and ortho to each of the two hydroxyls, and Y and Z are each O, and a ring atom of X is linked directly to the sp carbon atom adjacent to X, then substituted with H, OH, Cl, Br, I, amino, cyano, alkyl, alkoxy, alkenyl, or alkenyloxy; and each of Y and Z is independently selected from O, S, and NH; or a pharmaceutically acceptable salt or ester thereof.</description><edition>6</edition><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020808&DB=EPODOC&CC=AU&NR=751213B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020808&DB=EPODOC&CC=AU&NR=751213B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ALEXANDRA SANTANA-SORENSON</creatorcontrib><creatorcontrib>JACK B JIANG</creatorcontrib><creatorcontrib>WAI-LAM ALEX CHU</creatorcontrib><creatorcontrib>THOMAS B. JENSEN</creatorcontrib><creatorcontrib>JAMES B. MCALPINE</creatorcontrib><creatorcontrib>CATHERINE NOBLE</creatorcontrib><creatorcontrib>SUNIL RATNAYAKE</creatorcontrib><creatorcontrib>BIRGITTE SOKILDE</creatorcontrib><creatorcontrib>ANGELA M. STAFFORD</creatorcontrib><creatorcontrib>FLEMMING R. JENSEN</creatorcontrib><title>Substituted aurone derivatives</title><description>A method for treating a microbial infection is disclosed. The method includes administering to a patient a pharmaceutical composition containing a compound of formula (IA) where each R is independently H, OH, Br, Cl, I, amino, thiol, nitro, C1-4 alkoxy, C1-4 alkenyloxy, C2-6 alkoxyalkyleneoxy, C1-4 alkylthio, C3-18 alkyl, or C3-18 alkenyl; or two adjacent R's, taken together, are a C2-18 bivalent moiety containing at least one oxygen atom, substituted or disubstituted with A or B or both, A being H, OH, Br, Cl, I, amino, or thiol, and B being H, C1-10 alkyl, C2-18 alkenyl, or C6-18 aryl; provided at least two Rs are not H; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with two substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with three substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a prenyl substituent and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be H or OH; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a substituent containing three rings and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; X is C4-10 alkyl, C4-20 alkenyl, or a C4-20 single, C6-20 bridged, or C6-20 fused ring moiety containing cycloalkyl, cycloalkenyl, aryl, heterocycle, or heteroaryl, where X is substituted with H, OH, Cl, Br, I, amino, cyano, nitro, alkyl, alkoxy, alkenyl, or alkenyloxy; provided that if X is a heteroaryl or heterocyclic moiety where two Rs are each OH and meta to each other, then the remaining R is H and ortho to each of the two hydroxyls, and Y and Z are each O, and a ring atom of X is linked directly to the sp carbon atom adjacent to X, then substituted with H, OH, Cl, Br, I, amino, cyano, alkyl, alkoxy, alkenyl, or alkenyloxy; and each of Y and Z is independently selected from O, S, and NH; or a pharmaceutically acceptable salt or ester thereof.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJALLk0qLsksKS1JTVFILC3Kz0tVSEktyixLLMksSy3mYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxjqHmpoZGhsZOTkbGRCgBAPG_JM0</recordid><startdate>20020808</startdate><enddate>20020808</enddate><creator>ALEXANDRA SANTANA-SORENSON</creator><creator>JACK B JIANG</creator><creator>WAI-LAM ALEX CHU</creator><creator>THOMAS B. JENSEN</creator><creator>JAMES B. MCALPINE</creator><creator>CATHERINE NOBLE</creator><creator>SUNIL RATNAYAKE</creator><creator>BIRGITTE SOKILDE</creator><creator>ANGELA M. STAFFORD</creator><creator>FLEMMING R. JENSEN</creator><scope>EVB</scope></search><sort><creationdate>20020808</creationdate><title>Substituted aurone derivatives</title><author>ALEXANDRA SANTANA-SORENSON ; JACK B JIANG ; WAI-LAM ALEX CHU ; THOMAS B. JENSEN ; JAMES B. MCALPINE ; CATHERINE NOBLE ; SUNIL RATNAYAKE ; BIRGITTE SOKILDE ; ANGELA M. STAFFORD ; FLEMMING R. JENSEN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU751213BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2002</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ALEXANDRA SANTANA-SORENSON</creatorcontrib><creatorcontrib>JACK B JIANG</creatorcontrib><creatorcontrib>WAI-LAM ALEX CHU</creatorcontrib><creatorcontrib>THOMAS B. JENSEN</creatorcontrib><creatorcontrib>JAMES B. MCALPINE</creatorcontrib><creatorcontrib>CATHERINE NOBLE</creatorcontrib><creatorcontrib>SUNIL RATNAYAKE</creatorcontrib><creatorcontrib>BIRGITTE SOKILDE</creatorcontrib><creatorcontrib>ANGELA M. STAFFORD</creatorcontrib><creatorcontrib>FLEMMING R. JENSEN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ALEXANDRA SANTANA-SORENSON</au><au>JACK B JIANG</au><au>WAI-LAM ALEX CHU</au><au>THOMAS B. JENSEN</au><au>JAMES B. MCALPINE</au><au>CATHERINE NOBLE</au><au>SUNIL RATNAYAKE</au><au>BIRGITTE SOKILDE</au><au>ANGELA M. STAFFORD</au><au>FLEMMING R. JENSEN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Substituted aurone derivatives</title><date>2002-08-08</date><risdate>2002</risdate><abstract>A method for treating a microbial infection is disclosed. The method includes administering to a patient a pharmaceutical composition containing a compound of formula (IA) where each R is independently H, OH, Br, Cl, I, amino, thiol, nitro, C1-4 alkoxy, C1-4 alkenyloxy, C2-6 alkoxyalkyleneoxy, C1-4 alkylthio, C3-18 alkyl, or C3-18 alkenyl; or two adjacent R's, taken together, are a C2-18 bivalent moiety containing at least one oxygen atom, substituted or disubstituted with A or B or both, A being H, OH, Br, Cl, I, amino, or thiol, and B being H, C1-10 alkyl, C2-18 alkenyl, or C6-18 aryl; provided at least two Rs are not H; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with two substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl substituted with three substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a prenyl substituent and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be H or OH; further provided that when each of two Rs is one of OH, C1-4 alkoxy, C1-4 alkenyloxy, or C2-6 alkoxyalkyleneoxy, and X is phenyl subsituted with a substituent containing three rings and with two additional substituents independently selected from OH, alkoxy, and alkenyloxy, the remaining R cannot be prenyl; X is C4-10 alkyl, C4-20 alkenyl, or a C4-20 single, C6-20 bridged, or C6-20 fused ring moiety containing cycloalkyl, cycloalkenyl, aryl, heterocycle, or heteroaryl, where X is substituted with H, OH, Cl, Br, I, amino, cyano, nitro, alkyl, alkoxy, alkenyl, or alkenyloxy; provided that if X is a heteroaryl or heterocyclic moiety where two Rs are each OH and meta to each other, then the remaining R is H and ortho to each of the two hydroxyls, and Y and Z are each O, and a ring atom of X is linked directly to the sp carbon atom adjacent to X, then substituted with H, OH, Cl, Br, I, amino, cyano, alkyl, alkoxy, alkenyl, or alkenyloxy; and each of Y and Z is independently selected from O, S, and NH; or a pharmaceutically acceptable salt or ester thereof.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_AU751213BB2 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | Substituted aurone derivatives |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T14%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ALEXANDRA%20SANTANA-SORENSON&rft.date=2002-08-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU751213BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |